文献速递消化道肿瘤放疗姑息放疗与转移瘤

纳武利尤单抗联合放疗治疗不可切除晚期或复发胃癌:CIRCUIT试验5年更新

Nivolumab in combination with radiotherapy for unresectable advanced or recurrent gastric cancer (CIRCUIT trial): A 5-year update of the progression-free survival and local control outcomes.
PubMed 文献 · Radiother Oncol · 2026-03-19

CIRCUIT试验为单臂1/2期研究,纳入41例化疗后进展的不可切除晚期或复发胃癌患者,接受纳武利尤单抗联合放疗(最大或症状性肿瘤22.5 Gy/5次/5天)。5年更新显示中位生存7.3个月,5年总生存率10.8%、无进展生存率5.0%,照射肿瘤5年局部控制率57.5%,未观察到放疗相关严重不良事件。

要点

  • 5年总生存率10.8%,无进展生存率5.0%,2例无进展生存超5年。
  • 照射肿瘤5年局部控制率57.5%,中位局部控制期49.8个月。
  • 未观察到放疗相关严重不良事件,姑息剂量下局部控制良好。

核心结论

  • 纳武利尤单抗联合放疗安全,且似乎对生存有益。
  • 即使采用姑息性照射剂量,照射肿瘤仍获得良好局部控制率。

研究设计与样本

  • 单臂1/2期试验(CIRCUIT),纳入41例原发和二级化疗后进展的不可切除晚期或复发胃癌患者。
  • 3例照射多个部位,10例首次照射后对新出现肿瘤追加照射,共评估65个照射野。

主要发现

  • 中位生存时间7.3个月,中位至进展时间3.0个月。
  • 1年总生存率29.6%、无进展生存率7.5%;2年分别为16.2%和7.5%;5年分别为10.8%和5.0%。
  • 2例患者无疾病进展生存超过5年。
  • 照射肿瘤1年、2年、5年局部控制率分别为84.8%、71.8%、57.5%,中位局部控制期49.8个月。
  • 未观察到放疗相关严重不良事件。

关键数值与推荐

  • 放疗剂量方案:最大或症状性肿瘤22.5 Gy/5次/5天。
  • 5年总生存率10.8%,5年无进展生存率5.0%。
  • 照射肿瘤5年局部控制率57.5%,中位局部控制期49.8个月。

临床怎么用

  • 对化疗后进展的不可切除晚期或复发胃癌,可考虑纳武利尤单抗联合姑息性放疗。
  • 姑息性照射剂量(22.5 Gy/5次)即可获得较好局部控制,且未增加放疗相关严重不良事件。
  • 对多发肿瘤或多器官受累患者,可照射最大或症状性肿瘤,并可根据新出现肿瘤追加照射。

局限性

  • 单臂1/2期试验,无对照组,样本量41例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We have previously reported a single-arm, phase 1/2 trial against unresectable advanced or recurrent gastric cancer (GC) treated with a combination of radiotherapy and nivolumab (CIRCUIT trial). We present the 5-year updated results of the progression-free survival (PFS) and local control (LC) rates. MATERIALS AND METHODS: We enrolled 41 patients with unresectable advanced or recurrent GC who developed progression after the primary and secondary chemotherapies with more than one tumor assessable by diagnostic imaging. Thirty-three patients had five or more tumors and 34 had two or more organs with cancer. The largest or symptomatic tumors were irradiated in 22.5 Gy/5 fractions/5 days. Three patients had multiple sites irradiated. Ten patients underwent irradiation of additional newly appeared tumors after the first irradiation. A total of 65 irradiated fields were evaluated. RESULTS: The median survival time and time to progression were 7.3 and 3.0 months, respectively. The overall survival and PFS rates were 29.6% and 7.5% at 1 year, 16.2% and 7.5% at 2 years, and 10.8% and 5.0% at 5 years, respectively. Two patients have lived without disease progression for >5 years. The median LC period was 49.8 months. The LC rates at 1, 2, and 5 years for the irradiated tumor were 84.8%, 71.8%, and 57.5%, respectively. Severe adverse events related to radiotherapy were not observed. CONCLUSION: The addition of radiotherapy to nivolumab therapy was safe and seemed to be beneficial for survival. Furthermore, a good LC rate was observed even with administering a palliative irradiation dose.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Suzuki Y, Yoshida D, Mimura K, et al. Nivolumab in combination with radiotherapy for unresectable advanced or recurrent gastric cancer (CIRCUIT trial): A 5-year update of the progression-free survival and local control outcomes. Radiother Oncol. 2026. PMID: 41862024. doi:10.1016/j.radonc.2026.111494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。